Hudson Institute has a strong focus on taking research discoveries to the clinic through commercial partnerships.
Our Business Development Office works closely with our scientists and with the pharmaceutical and biotechnology sector to take Hudson research discoveries closer to the clinic.
They look after all aspects of commercialisation and commercial contracts, from evaluating invention disclosures to legally capturing intellectual property through negotiation and managing commercial agreements.
Rob Merriel BA, Grad Dip (Psych), Grad Dip (Accounting), CPA
Chief Commercialisation Officer (CCO)
As CCO at Hudson, Rob has an overall portfolio responsibility for the management and commercialisation of Institute IP. He has an extensive understanding of this area, with more than 35 years’ experience working in medical research (Baker IDI), healthcare (Melbourne Health and Southern Health) and commercial organisations (Pacific Dunlop and Deloitte Consulting). This experience has encompassed managing and licensing IP portfolios, engaging with venture capital funds, preparation of business cases and financial modelling for commercial initiatives, and identification of industry engagement opportunities.
Rob also has extensive knowledge of clinical trials and human research ethics processes from his time working in the Research Directorate of the Royal Melbourne Hospital. Rob was previously the director and company secretary of several biotechnology-focused companies, including BioGrid Australia, Biocomm, the Australian Technology Fund and Evivar, and is current company secretary of Hudson.
Nadine Brew BA, BSc(Hons), PhD
Business Development Officer
Nadine is a Churchill Fellowship and NHMRC scholarship recipient with over 10 years of experience in biomedical research in Australia and the United States. With training and experience in medical research commercialisation from Monash Innovation and the Medical Research Commercialisation Fund, in 2108 she was selected to participate in The Observership Program.
At Hudson, Nadine manages and contributes to a range of activities including opportunity identification, research and marketing of commercial projects, investor and partner relations, IP management and establishment of start-up companies from the Institute’s IP. Nadine has a PhD in neonatal lung injury from Monash University, as well as a BSc with first class honours from the University of Melbourne and a BA from Deakin University.
Kate Mackin BA, BSc(Hons), PhD
Business Development Coordinator
Kate joined Hudson Institute’s Business Development Office in August 2017 to support the commercialisation of promising inventions from the Institute’s research staff. She contributes to invention disclosure assessments, proposal and contract preparation, marketing, technology development, and IP management.
Kate has a broad knowledge of the Institute, having previously worked as Executive Assistant to the Director and CEO. She comes from a research background, attaining her PhD from the Department of Microbiology at Monash University and working as a postdoctoral research officer before joining Hudson Institute at the start of 2016.